|Therapeutic Class:||Calcium-channel blockers|
|Manufacturer:||Julphar Bangladesh Ltd.|
|Last Updated:||2020-11-21 18:15:00|
Raklopin Tablet contains Amlodipine. Raklopin uses:
Patients with mild to moderate hypertension (alone or in combination with other antihypertensives).
The treatment of chronic stable and vasospastic angina.
Raklopin Tablet contains Amlodipine 10 mg. Raklopin doses:
For treatment of both hypertension and angina pectoris, the usual initial dose is 5 mg once daily. If the desired therapeutic effect cannot be achieved within 2-4 weeks, the dose may be increased to a maximum dose of 10 mg once daily. Raklopin Tablet 10 mg once daily provides symptomatic improvement in patients with Raynaud's disease.
Use in children: Use of Raklopin Tablet in children (under 12 years of age) is not recommended.
Raklopin Tablet is generally well tolerated. The most commonly observed side effects are headache, peripheral oedema, palpitations, flushing, dizziness, nausea, abdominal pain.
Raklopin Tablet is a Dihydropyridine Calcium antagonist that inhibits the transmembrane influx of Calcium ions into cardiac and vascular smooth muscle. It has greater affinity towards vascular smooth muscle than on cardiac muscle. Raklopin Tablet is peripheral vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and thereby reduces blood pressure. Raklopin Tablet reduces tone, decreases coronary vasoreactivity and lowers cardiac oxygen demand by reducing after load.
Hypotension: Since the vasodilUse in renal failure
Although Raklopin Tablet is excreted primarily via kidney, mild renal impairment does not appear to have an effect on the plasma concentrations. Severe renal impairment may however require a dosage reduction. Raklopin Tablet is not dialyzable.
Use in patients with impaired hepatic function
Raklopin Tablet half-life is prolonged in patient with impaired hepatic function. Raklopin Tablet should therefore be administered at lower (5mg) initial dose in these patients.
Use in heart failure
An increased number of pulmonary oedema has been reported.atation induced by Raklopin Tablet is gradual in onset, acute hypotension has rarely been reported after oral administration of Raklopin Tablet. Nonetheless, caution should be exercised when administering the drug with any other peripheral vasodilator particularly in patients with severe aortic stenosis.
Cardiac failure: Patients with heart failure should be treated with caution. Calcium channel blockers, including Raklopin Tablet, should be usedwith caution in patients with congestive heart failure, as they may increase the risk of future cardiovascular events and mortality.
Beta blocker withdrawal: Raklopin Tablet gives no protection against the danger of abrupt beta blocker withdrawal; any such withdrawal should be gradualreduction of the dose of beta blocker.
Hepatic failure: The half-life of amlodipine is prolonged and AUC values are higher in patients with impaired liver function. Raklopin Tablet should therefore be initiated at the lower end of the dosing range and caution should be used, both on initial treatment and when increasing the dose. Slow dose titration and careful monitoring may be required in patients with severe hepatic impairment.
Use of Raklopin Tablet together with thiazide diuretics or angiotensin-converting-enzyme inhibitors in the treatment of hypertension is additive. There are no hazardous interaction of Raklopin Tablet with Digoxin, Cimetidine, Warfarin and food.
Pregnancy: Safety in pregnancy has not been established.
Lactation: It is not known whether Raklopin Tablet is excreted in breast milk. It is advised to stop breastfeeding during treatment with Raklopin Tablet.
Raklopin Tablet is contraindicated in patients with-
Children with hypertension from 6 years to 17 years of age: 2.5 mg once daily as a starting dose, up-titrated to 5 mg once daily if blood pressure goal is not achieved after 4 weeks. Doses in excess of 5 mg daily have not been studied in pediatric patients.
Children under 6 years old: The effect of amlodipine on blood pressure in patients less than 6 years of age is not known.
Elderly: Raklopin Tablet used at similar doses in elderly or younger patients is equally well tolerated. Normal dosage regimens are recommended in the elderly, but increase of the dosage should take place with care.
Renal impairment: Changes in amlodipine plasma concentrations are not correlated with degree of renal impairment, therefore the normal dosage is recommended. Raklopin Tablet is not dialysable.
Hepatic impairment: Dosage recommendations have not been established in patients with mild to moderate hepatic impairment; therefore dose selection should be cautions and should start at the lower end of the dosing range. The pharmacokinetics of Raklopin Tablet have not been studied in severe hepatic impairment. Raklopin Tablet should be initiated at the lowest dose (2.5 mg once daily) and titrated slowly in patients with severe hepatic impairment.
There is no well documented experience with Raklopin Tablet overdosage. In case of clinically significant hypotension due to Raklopin Tablet over dosage, calls for active cardiovascular support including monitoring of cardiac and respiratory function, elevation of extremities and attention to circulating fluid volume and urine output. Since Raklopin Tablet is highly protein-bound, dialysis is unlikely to be of benefit.
Keep out of the reach of children. Store below 30° C. Keep in the original package in a cool & dry place in order to protect from light and moisture.
Raklopin Tablet price in Bangladesh 8.40